How the FDA Evaluates Drug Safety

In 1980, AIDS activist and former Jesuit seminarian Martin Delaney was suffering from life-threatening hepatitis. He treated it with drugs then unapproved in the U.S. In 1985, Delaney founded Project Inform--which gathers information and facilitates access to AIDS treatments. Delaney has helped bring Compound Q, an unapproved AIDS drug, out of China. His life and work are discussed extensively in Jonathon Kwitny's controversial new book, "Acceptable Risks."

Journalist Philip Hilts is a longtime correspondent on health and science policy for The New York Times. He broke the now-famous story of the Brown and Williamson tobacco industry papers, and is the author of "Smokescreen: The Truth Behind the Tobacco Industry Cover-Up." He'll discuss recent developments in the industry: the federal court ruling allowing the FDA to label tobacco a drug, and the historic admission by the Liggett Company that cigarettes are a health hazard and addictive.

As the cost of prescription medication soars, consumers are increasingly taking generic drugs: low-cost alternatives to brand-name medicines. Often health insurance plans require patients to switch to generics as a way of controlling costs. But journalist Katherine Eban warns that some of these medications might not be as safe, or effective, as we think.